Is Janux Therapeutics, Inc. (JANX) a Buy, Sell, or Hold?
NASDAQ : JANX
Janux Therapeutics, Inc.
$16.03 USD
$0.25 (1.58%)
- Volume
- 829.62K
- Average Volume
- 1.13M
- Market Capitalization
- $977.58M
- P/E Ratio
- -8.71
- Dividend Yield
- 0.00%
- Price Target
- $22.00
- Year High
- $35.34
- Year Low
- $12.12
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $17.01
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | David Alan Campbell |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | JANX |
| CUSIP | 47103J105 |
| CIK | 0001817713 |
| Web | https://www.januxrx.com |
| Phone | 858 750 4700 |
| Currency | USD |
| Employees | 109 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.02 |
| Payout Ratio | 0.00 |
| Current Ratio | 17.01 |
| Quick Ratio | 17.01 |
| Cash Ratio | 0.88 |
Sales & Book Value
| Annual Sales | $10M |
| Price / Sales | 45.23 |
| Cash Flow | -1.25 |
| Price / Cash Flow | -12.45 |
| Price / Book | 1.07 |
Price Target and Rating
| Average Stock Price Forecast | $22.00 |
| High Stock Price Forecast | $36.00 |
| Low Stock Price Forecast | $14.00 |
| Forecast Upside/Downside | -27.14% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 15 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | -$1.83 |
| Trailing P/E Ratio | -8.71 |
| PEG Ratio | 0.25 |
| P/E Growth | 0.25 |
| Net Income | -$113.62M |
| Net Margin | -529.67% |
| Pretax Margin | -529.67% |
| Return on Equity | -11.85% |
| Return on Assets | -11.13% |
Financials Score
| AltmanZ Score | 7.01 |
| Piotroski Score | 3.00 |
| Working Capital | 943.13M |
| Total Assets | 1.03B |
| Ebit | -114.48M |
| Market Cap | 977.58M |
| Total Liabilities | 86.69M |
Poll Results
About Janux Therapeutics, Inc. (NASDAQ:JANX) Stock
Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. In addition to its TRACTr pipeline, the company is also developing a Tumor Activated Immunomodulator (TRACIr) — a costimulatory bispecific candidate designed to enhance T cell anti-tumor activity by engaging with programmed death-ligand 1 ... and CD28. Furthermore, a specific focus for their EGFR-TRACTr program is addressing epidermal growth factor receptor, a target prevalent in many cancer types and already a focus of numerous approved monoclonal antibody treatments. Janux Therapeutics, Inc. was founded in 2017 and is headquartered in La Jolla, California.
2026-05-28 10:56:12
The mean of analysts' price targets for Janux Therapeutics (JANX) points to a 155.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here's Why You Should Add JANX Stock to Your Portfolio Now
2026-05-26 12:31:08
Janux Therapeutics advances multiple oncology and immune therapy programs with key clinical updates, new studies and expanded partnerships with BMY and MRK.
Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Lags Revenue Estimates
2026-05-07 20:11:30
Janux Therapeutics, Inc. (JANX) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.5. This compares to a loss of $0.38 per share a year ago.
Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
2026-05-07 16:01:00
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the quarter ended March 31, 2026, and provided a business update. "Our commitment to advancing a prostate cancer franchise is demonstrated by our continued progress with JANX007, clinical initiation of JANX014, and advancement of JANX013 toward the clinic,” said David Campbell, Ph.D., Pr.
How Much Upside is Left in Janux Therapeutics (JANX)? Wall Street Analysts Think 180.44%
2026-05-07 10:55:35
The consensus price target hints at an 180.4% upside potential for Janux Therapeutics (JANX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Janux Therapeutics: Strong Buy As Pipeline Advances, Stock Trades Below Cash Value
2026-05-04 19:33:55
Janux Therapeutics, Inc. is upgraded to Strong Buy, trading below cash value with a robust cash runway and validated technology platforms. Discontinuation of JANX008 demonstrates financial discipline, reallocating resources to higher-potential assets and further validating the TRACTr platform. Strategic partnerships with Merck and BMY could yield up to $1.8 billion in milestones plus royalties, supporting long-term value creation.
Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development
2026-04-27 16:01:00
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (“Janux”), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that it will discontinue further clinical development of JANX008, its EGFR-targeted Tumor Activated T Cell Engager (TRACTr) program. Following completion of the Phase 1a portion of the study, which included dose escalation and expansion cohorts across multiple solid tumor indications, and an internal revie.
Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014
2026-04-16 16:01:00
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that the first patient has been dosed in a Phase 1 clinical trial of JANX014 in patients with metastatic castration-resistant prostate cancer (mCRPC). JANX014 is a double-masked, prostate-specific membrane antigen (PSMA) directed T cell engager (TCE) designed to leverage Janux's tumor-activated technology pl.
Frequently Asked Questions
-
What is the current Janux Therapeutics, Inc. (JANX) stock price?
-
Janux Therapeutics, Inc.(NASDAQ:JANX) stock price is $16.03 in the last trading session. During the trading session, JANX stock reached the peak price of $35.34 while $12.12 was the lowest point it dropped to. The percentage change in JANX stock occurred in the recent session was 1.58% while the dollar amount for the price change in JANX stock was $0.25.
-
JANX's industry and sector of operation?
-
The NASDAQ listed JANX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of JANX?
-
Thomas Diraimondo | Chief Scientific Officer
Mandie Forman-Sklansky | Head of Human Resources
William Y. Go | Chief Medical Officer
James Pennington | General Counsel & Corporate Secretary
Matt Whitmire | Vice President of Finance -
How many employees does JANX have?
-
Number of JANX employees currently stands at 109. JANX operates from 11099 North Torrey Pines Road, San Diego, CA 92037, US.
-
Link for JANX official website?
-
Official Website of JANX is: https://www.januxrx.com
-
How do I contact JANX?
-
JANX could be contacted at phone #858 750 4700 and can also be accessed through its website. JANX operates from 11099 North Torrey Pines Road, San Diego, CA 92037, US.
-
How many shares of JANX are traded daily?
-
The average number of JANX shares traded daily for last 3 months was 1.13M.
-
What is the market cap of JANX currently?
-
The market value of JANX currently stands at $977.58M with its latest stock price at $16.03